Reproductive health care providers are highly likely to encounter patients who misuse substances such as opioids, alcohol, cannabis, and methamphetamines. In 2019, about 7.2 million women reported a substance abuse disorder, largely concerning alcohol use. What about the opioid crisis that has been developed over the years? In that 2019 survey, about 5 million women reported misusing opioids, with about 700,000 of them meeting the criteria for opioid use disorder. And since 2019? Nearly one third of survey respondents who use alcohol or other drugs reported an increase in their use during the Covid-19 pandemic.
During the last week of September 2021, 500 participants in the Contraceptive Technology virtual conference learned about three new contraceptives that I want to tell you about. Innovation means nothing unless it leads to a change in practices. The answer is in the hands of everyone providing contraceptives and of students of this field—offer your patients the option of any of these three exciting new methods: the drospirenone-containing progestin-only pill, the 52 mg LNG IUDs as emergency contraceptives, and Depo SQ for self-injection at home.
Registered for the 2021 Contraceptive Technology Virtual Conference, September 22-24? We look forward to “seeing” you there! Helpful directions follow, and are also available at http://contraceptivetechconf.com/attendee-instructions/.
Need help logging in? Your confirmation email included a user name, password, and login link to access the conference. Be sure to check your spam if you didn’t see it come through. Can’t find it? Email us at conference [at] contraceptivetechnology.com